Concepedia

Jens Eilbracht

JE

3

Publications

652

Citations

3

H-Index

2013

Active since

Affiliations

Boehringer Ingelheim (Germany)(Current)

Profil Institute for Metabolic Research

Medical University of Graz

Boehringer Ingelheim (Canada)

Boehringer Ingelheim (France)

Jens Eilbracht is an author at Boehringer Ingelheim (Germany) specializing in cardiovascular disease, diabetes, and pharmacotherapy.

Top concepts

Publications per year

2013–2016

3

Publications

3

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Roden, Jianping Weng, Jens Eilbracht et al. · The Lancet Diabetes & Endocrinology · 2013 · 438 citations

, , +8

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( <scp>EASE</scp> ‐1)

Thomas R. Pieber, Susanne Famulla, Jens Eilbracht et al. · Diabetes Obesity and Metabolism · 2015 · 162 citations · Full text

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

Susanne Famulla, Thomas R. Pieber, Jens Eilbracht et al. · Diabetes Technology & Therapeutics · 2016 · 52 citations

Rows per page

1–3 of 3